Background & aims: Therapeutic drug monitoring might be used to personalize infliximab treatment of patients with ulcerative colitis (UC), although exposure thresholds associated with endoscopic healing are uncertain. We aimed to determine infliximab concentration thresholds associated with endoscopic outcomes during induction and maintenance therapy for patients with UC.


Treatment Outcome, Infliximab, Anti-TNF, Therapeutic drug monitoring, ACT-1, Drug Therapy, ACT-2, Ulcerative Colitis, Exposure-Based Dosing, Pathology, Pharmacokinetics, Colonoscopy, Intestinal Mucosa, therapeutic use, Gastrointestinal Agents

Read More